SCHEMBL3083774

SCHEMBL3083774

O=C(c1coc(-c2ccc(OCCCCl)cc2)n1)N1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.48
HPGD P15428 4/20 0.46
ALDH1A1 P00352 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PDE4B Q07343 4/20 0.43
PDE4D Q08499 3/20 0.43
KCNH2 Q12809 1/20 0.43
RAB9A P51151 3/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3079473 0.99 HRH3 (0.50) HRH3HPGDALDH1A1KMT2AMEN1
SCHEMBL3068645 0.91 HRH3 (0.51) HRH3SMN1; SMN2PDE4BPDE4DRAB9A
SCHEMBL3083527 0.88 KMT2A (0.45) HRH3KMT2AMEN1SMN1; SMN2KCNH2
SCHEMBL3081848 0.82 HRH3 (0.54) HRH3HPGDALDH1A1KMT2AMEN1
SCHEMBL3497033 0.82 PDE4B (0.44) SMN1; SMN2PDE4BPDE4DRAB9ANPC1
SCHEMBL3078611 0.82 HRH3 (0.57) HRH3KCNH2
SCHEMBL3075185 0.82 HRH3 (0.46) HRH3
SCHEMBL3082008 0.82 HDAC1 (0.47) HRH3ALDH1A1SMN1; SMN2PDE4BPDE4D
SCHEMBL3080685 0.81 HRH3 (0.56) HRH3HPGDALDH1A1KMT2AMEN1
SCHEMBL3078871 0.81 HRH3 (0.56) HRH3HPGDALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP claimed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR HRH3 4/4885HPGD 2325/4885ALDH1A1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.